Measles

Summary

Measles (MONDO:0004619) is a disease and 107 clinical trials. Top therapeutic interventions include hepatitis b virus hbsag surface protein antigen, rubella virus vaccine live, and bcg vaccine. A subtype of morbillivirus infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 107

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	measles
Mondo ID	MONDO:0004619
EFO	EFO:1002025
MeSH	D008457
DOID	DOID:8622
ICD-10-CM	B05
ICD-11	1826431497
NCIT	C96406
SNOMED CT	14189004
UMLS	C0025007
MedGen	6252
GARD	0027345
Is cancer (heuristic)	no

Also known as: Measles morbillivirus caused disease or disorder · Measles morbillivirus disease or disorder · Measles morbillivirus infectious disease · morbilli · rubeola · rubeola infection

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Paramyxoviridae infectious disease › morbillivirus infectious disease › measles

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Measles Virus, Live Attenuated	Approved (phase 4)
Sulfamethoxazole	Phase 3 (in late-stage trials)
Trimethoprim	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Measles Virus Vaccine Live, Mumps Virus Vaccine Live, Rubella Virus Vaccine Live.

Clinical trials & evidence

Clinical trials

Clinical trials: 107.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	35
Not specified	33
PHASE4	21
PHASE2	12
PHASE1/PHASE2	3
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04899765	PHASE4	RECRUITING	Measles and BCG Vaccines for Mother and Child
NCT00126997	PHASE4	COMPLETED	Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00168545	PHASE4	COMPLETED	Immunology of Non-specific Effects of Vaccine
NCT00168558	PHASE4	COMPLETED	Early Two-dose Measles Vaccination Trial
NCT00168571	PHASE4	COMPLETED	Long-term Follow-up of Measles Antibodies
NCT00168662	PHASE4	COMPLETED	Non-Specific Effects of Standard Titre Measles Vaccination
NCT00313950	PHASE4	COMPLETED	Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
NCT00326183	PHASE4	COMPLETED	Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
NCT00388440	PHASE4	COMPLETED	Assess GSK Biologicals’ MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
NCT00432731	PHASE4	COMPLETED	Safety Study of a Refrigerator-stable Formulation of VARIVAX®
NCT01770119	PHASE4	UNKNOWN	Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
NCT01777529	PHASE4	COMPLETED	Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
NCT02325310	PHASE4	COMPLETED	Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
NCT02643433	PHASE4	COMPLETED	Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines
NCT02880865	PHASE4	COMPLETED	Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
NCT03071575	PHASE4	COMPLETED	Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
NCT03160820	PHASE4	COMPLETED	Study on Immunization Schedule of Beijing Tiantan Biological’s Measles-mumps-rubella(MMR) Vaccine
NCT03330171	PHASE4	UNKNOWN	Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine
NCT05279248	PHASE4	UNKNOWN	The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
NCT05952505	PHASE4	UNKNOWN	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
NCT06331702	PHASE4	COMPLETED	Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
NCT06815835	PHASE3	NOT_YET_RECRUITING	Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
NCT07406360	PHASE3	NOT_YET_RECRUITING	A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
NCT00092391	PHASE3	COMPLETED	A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
NCT00092430	PHASE3	COMPLETED	Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
NCT00109343	PHASE3	COMPLETED	V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
NCT00127010	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00127023	PHASE3	COMPLETED	Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
NCT00168532	PHASE3	COMPLETED	Prophylactic Antibiotics in Measles
NCT00351923	PHASE3	COMPLETED	Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
NCT00384397	PHASE3	COMPLETED	A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT00402831	PHASE3	COMPLETED	ProQuad® Intramuscular vs Subcutaneous
NCT00406211	PHASE3	COMPLETED	Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
NCT00422292	PHASE3	COMPLETED	Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
NCT00432042	PHASE3	COMPLETED	Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
NCT00432523	PHASE3	COMPLETED	Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
NCT00483574	PHASE3	COMPLETED	Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
NCT00560755	PHASE3	COMPLETED	Safety Study of ProQuad® rHA in Infants (V221-037)
NCT00566527	PHASE3	COMPLETED	Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
NCT00751348	PHASE3	COMPLETED	Immunogenicity & Safety Study of GSK Biologicals’ Combined Measles-mumps-rubella-varicella Vaccine 208136

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	4	1
RUBELLA VIRUS VACCINE LIVE	3	3
BCG VACCINE	3	1